Search

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its financial …

… company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a … event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the …

… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on …

… Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, …

… NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the …

… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … against a key Axiomer patent protecting ADAR-mediated RNA editing Well-capitalized with €139 M, in cash and cash …

… to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple therapeutic …